Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Practical Implications of Using Olaratumab in Patients with STS

November 8th 2016

Registration Trials for Olaratumab and Doxorubicin for STS

November 8th 2016

FDA Approval of Olaratumab + Doxorubicin for STS

November 8th 2016

Multidisciplinary Care of STS

November 8th 2016

Disease State: Advanced Soft Tissue Sarcoma

November 8th 2016

Immunotherapy, MEK Inhibitor Combo Effective for BRAF Wild-Type Melanoma

November 8th 2016

The combination of atezolizumab and cobimetinib may lead to a higher overall response and a longer progression-free survival than either agent alone in patients with metastatic melanoma.

Dr. Christian Blank on Combining Immunotherapy Agents in High-Risk Melanoma

November 8th 2016

Christian Blank, MD, PhD, Netherlands Cancer Institute, discusses some of the early findings from the OpACIN trial testing a combination of ipilimumab and nivolumab in the neoadjuvant and adjuvant setting for patients with stage III melanoma.

Neoadjuvant Nivolumab/Ipilimumab Shows Early Promise for Stage III Melanoma

November 8th 2016

Neoadjuvant therapy with the combination of nivolumab and ipilimumab is plausible and effective but can induce a high level of adverse events calling for further research into better tolerated dosing schemes.

Dr. Ryan Sullivan on Treating BRAF-Mutant Patients With Melanoma

November 8th 2016

Ryan Sullivan, MD, Massachusetts General Hospital, discusses how best to treat patients with melanoma who have the BRAF mutation.

Atezolizumab Combos Highly Effective for Advanced Melanoma

November 7th 2016

The addition of the PD-L1 inhibitor atezolizumab to the MEK inhibitor cobimetinib and the BRAF inhibitor vemurafenib induced a high response rate for patients with BRAF-mutant unresectable melanoma.

Dr. Jason Luke on Sequencing Targeted and Immunotherapy Agents in BRAF+ Melanoma

November 4th 2016

Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine, discusses the role for immunotherapy and targeted agents in patients with BRAF-positive melanoma.

IDO Inhibitors for Melanoma

October 31st 2016

Emerging Immunotherapy Combinations for Melanoma

October 31st 2016

Looking to the Future of Melanoma

October 31st 2016

Sequencing Strategies for Recurrent/Refractory Melanoma

October 31st 2016

Treatment Beyond Melanoma Progression

October 31st 2016

Abscopal Effect and Pseudoprogression in Melanoma

October 31st 2016

Single vs Dual Checkpoint Inhibition in Melanoma

October 31st 2016

Questions About Sequencing in BRAF-Mutant Melanoma

October 31st 2016

Dual-Targeted Therapy for BRAF-Mutant Melanoma

October 31st 2016